| | |
|---|---|
| **Official Title:** | **A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)** |
| **NCT Number:** | NCT03126019 |
| **Document Date:** | Statistical Analysis Plan Version 2: 28 January 2021 |

# STATISTICAL ANALYSIS PLAN

## INCB 50465-203

## A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

| | |
|---|---|
| **IND Number:** | **121,474** |
| **EudraCT Number:** | **2017-001624-22** |
| **Sponsor:** | **Incyte Corporation**<br>**1801 Augustine Cut-Off**<br>**Wilmington, DE 19803** |
| **Protocol Version:** | **Protocol Amendment 9 dated 23 DEC 2019** |
| **CRF Approval Date:** | **13 NOV 2018** |
| **SAP Version:** | **Amendment 2** |
| **SAP Author:** | [redacted]**, PhD**<br>[redacted] **Biostatistics** |
| **Date of Plan:** | **28 JAN 2021** |

This study is being conducted in compliance with good clinical practice, including the archiving of essential documents.

# TABLE OF CONTENTS

## LIST OF TABLES



## LIST OF FIGURES

# LIST OF ABBREVIATIONS

| Abbreviation | Term |
|---|---|
| AE | adverse event |
| ALT | alanine aminotransferase |
| AST | aspartate aminotransferase |
| BMI | body mass index |
| bpm | beats per minute |
| CI | confidence interval |
| CMV | cytomegalovirus |
| CR | complete response |
| CRF | case report form |
| CRR | complete response rate |
| CT | computed tomography |
| CTCAE | common terminology criteria for adverse events |
| DOR | duration of response |
| ECG | electrocardiogram |
| ECOG | Eastern Cooperative Oncology Group |
| EWB | emotional well-being |
| [redacted] | [redacted] |
| [redacted] | [redacted] |
| FAS | full analysis set |
| FDA | Food and Drug Administration |
| FL | follicular lymphoma |
| FLIPI | Follicular Lymphoma International Prognostic Index |
| FWB | functional well-being |
| [redacted] | [redacted] |
| IDMC | independent Data Monitoring Committee |
| IRC | Independent Review Committee |
| LYMS | lymphoma subscale |
| MedDRA | Medical Dictionary for Regulatory Activities |
| [redacted] | [redacted] |
| MRI | magnetic resonance imaging |
| NCI | National Cancer Institute |
| NE | not evaluable |
| NHL | non-Hodgkin lymphoma |

| Abbreviation | Term |
|---|---|
| ORR | objective response rate |
| OS | overall survival |
| PD | progressive disease |
| PFS | progression-free survival |
| PJP | *Pneumocystis jirovecii* pneumonia |
| [redacted] | [redacted]c |
| PP | per protocol (population) |
| PR | partial response |
| PT | preferred term |
| PWB | physical well-being |
| QD | once daily |
| QTcB | QT interval corrected using Bazett's formula |
| QTcF | QT interval corrected using Fridericia's formula |
| SAP | Statistical Analysis Plan |
| SD | stable disease |
| SOC | system organ class |
| SWB | social/family well-being |
| TEAE | treatment-emergent adverse event |
| ULN | upper limit of normal |
| WHO | World Health Organization |

# 1. INTRODUCTION

This is a Phase 2, multicenter, open-label study designed to evaluate the efficacy and safety of 2 INCB050465 treatment regimens in participants with relapsed or refractory FL who have received at least 2 prior systemic therapies.

Section 1 of the Protocol provides a detailed description of the investigational product, target patient population, rationale for doses to be examined, and potential risks and benefits of treatment with INCB050465.

The purpose of this SAP is to provide details of the statistical analyses that have been outlined in the study INCB 50465-203 Protocol. The scope of this plan includes the interim and final analyses that are planned and will be executed by the Department of Biostatistics or designee, [redacted]

# 2. STUDY INFORMATION, OBJECTIVES, AND ENDPOINTS

## 2.1. Protocol and Case Report Form Version

This SAP is based on INCB 50465-203 Protocol Amendment 9 dated 23 DEC 2019 and CRFs approved 13 NOV 2018. Unless superseded by an amendment, this SAP will be effective for all subsequent Protocol amendments and CRF versions.

## 2.2. Study Objectives and Endpoints

Table 1 presents the objectives and endpoints.

**Table 1: Objectives and Endpoints**

| Objectives | Endpoints |
|---|---|
| **Primary** | |
| To assess the efficacy of INCB050465 in terms of ORR in participants with relapsed or refractory FL. | ORR defined as the percentage of participants with a CR or PR as defined by revised response criteria for lymphomas (Cheson et al 2014), as determined by an IRC. |
| **Secondary** | |
| To assess CRR. | CRR defined as the percentage of participants with a CR as defined by revised response criteria for lymphomas (Cheson et al 2014), as determined by an IRC. |
| To assess DOR. | DOR defined as the time from first documented evidence of CR or PR until disease progression or death from any cause among participants who achieve an objective response (ie, CR or PR), as determined by radiographic disease assessment provided by an IRC. |
| To assess PFS. | PFS defined as the time from the date of the first dose of study treatment until the earliest date of disease progression, as determined by radiographic disease assessment provided by an IRC, or death from any cause. |
| To assess OS. | OS defined as the time from the date of the first dose of study treatment until death from any cause. |
| To assess best percentage change in target lesion size. | Best percentage change in target lesion size from baseline, where target lesion size is measured by the sum of the product of the diameters of all target lesion sizes. |
| To characterize the safety and tolerability of INCB050465. | Safety measured by clinical assessments, including vital signs and physical examinations, 12-lead ECGs, chemistry and hematology laboratory values, and AEs. |

**Table 1: Objectives and Endpoints (Continued)**

[redacted]

## 3. STUDY DESIGN

This is a Phase 2, multicenter, open-label study evaluating 2 INCB050465 treatment regimens based on the primary endpoint of ORR. Participants with relapsed or refractory FL (Grades 1, 2, or 3a) who have received at least 2 prior systemic therapies and who are ineligible for hematopoietic stem cell transplant will be screened for eligibility. A total of approximately 120 participants will be enrolled. The first 50 participants enrolled will be assigned at a 1:1 ratio to 2 study treatment regimens as follows (see Figure 1):

- Group A: INCB050465 20 mg QD for 8 weeks followed by 20 mg once weekly
- Group B: INCB050465 20 mg QD for 8 weeks followed by 2.5 mg QD

The remaining 70 participants will be allocated to 1 of the 2 treatment groups to better understand the safety and efficacy of that treatment regimen. The treatment group will be selected after evaluation of emerging safety and efficacy data from this and other monotherapy studies of INCB050465 in NHL, which are evaluating the same or similar dosing regimens, and will be implemented after the first 50 participants are enrolled. Participants allocated to the nonselected treatment regimen may switch to the selected treatment regimen or remain on their current treatment regimen, provided they have not met study-treatment withdrawal criteria, and there are no safety concerns for their current treatment regimen. There will be no rebaselining for participants who switch treatment regimens, and all participants will continue to follow the same assessment schedule.

Participants may receive treatment until disease progression, death, unacceptable toxicity, or consent withdrawal, whichever occurs first. Participants will be evaluated for ORR by an IRC and followed for CRR, DOR, PFS, OS, and safety.

An interim futility analysis is planned when the first 50 participants (Group A and Group B combined) have been evaluated for response or have permanently discontinued study treatment because of disease progression, withdrawal of consent, or death. The study will be terminated

for futility if ≤ 18 of the 50 participants have responded (ie, CR or PR) based on assessments provided by the IRC.

**Figure 1: Study Design**




[a] The first 50 subjects will be assigned at a 1:1 ratio to treatment Group A and treatment Group B. The remaining 70 subjects will be enrolled to the selected treatment Group (ie, either Group A or Group B).

[b] A futility analysis will be performed when the first 50 subjects have been evaluated for response.

## 3.1. Randomization

Not applicable.

## 3.2. Control of Type I Error

There will not be any statistical comparison between the 2 treatment groups. Two-sided 95% CIs will be reported for all analyses when appropriate.

No adjustment for alpha-spending is considered as there are no plans to stop the study early for overwhelming efficacy. An IDMC will be assembled to monitor safety data and study conduct on a regular and ongoing basis during the study. The IDMC will also be charged with evaluating interim futility results. See Section 10 for details regarding interim analyses conducted in this study.

## 3.3. Sample Size Considerations

Approximately 120 participants will be enrolled and assigned to either treatment Group A or Group B. The first 50 participants will be assigned at a 1:1 ratio to 2 treatment groups, and the remaining 70 participants will be allocated to the selected treatment group based on the emerging safety and efficacy data from this and other monotherapy studies of INCB050465 in NHL that are evaluating the same or similar dosing regimens. If the true ORR is 51% for participants in Group A and Group B, then with 120 total participants, there is approximately 93% probability of observing the lower bound of the 95% CI of ORR ≥ 35%.

## 3.4. Schedule of Assessments

See Protocol Amendment 9 dated 23 DEC 2019 for a full description of all study procedures and assessment schedules for this study.

# 4. DATA HANDLING DEFINITIONS AND CONVENTIONS

## 4.1. Scheduled Study Evaluations and Study Periods

### 4.1.1. Day 1

Day 1 is the date that the first dose of study drug (INCB050465) is administered to the participants.

### 4.1.2. Study Day

If a visit/reporting date is on or after Day 1, then the study day at the visit/reporting date will be calculated as

Day # = (Visit/Reporting Date – Day 1 date + 1).

If the visit/reporting date is before Day 1, then the study day at the visit/reporting date will be calculated as

Day # = (Visit/Reporting Date – Day 1 date).

A study day of –1 indicates 1 day before Day 1.

### 4.1.3. Baseline Value

Baseline is the last nonmissing measurement obtained before the first administration of INCB050465, unless otherwise defined.

When scheduled assessments and unscheduled assessments occur on the same day and time of the assessment or time of first dose is not available, use the following convention to determine baseline:

- If both a scheduled and an unscheduled visit are available on the day of the first dose and the time is missing, use the scheduled assessment as baseline.
- If all scheduled assessments are missing on the day of the first dose and an unscheduled assessment is available, use the unscheduled assessment as baseline.

### 4.1.4. Handling of Missing and Incomplete Data

In general, values for missing data will not be imputed unless methods for handling missing data are specified in this section or relevant sections. The original reported dates collected on the eCRF should be used in all relevant listings. The following rules will be used for handling missing or partial dates for analyses requiring dates.

When calculating time since initial diagnosis of cancer, partial diagnosis date will be handled in the calculation as follows:

- If only the day is missing, then the first day of the month will be used.
- If both the month and day are missing, then 01 JAN will be used.
- Otherwise, the time since diagnosis will not be calculated.

When the date of the last dose is used in deriving variables such as duration of treatment or TEAE flag, missing or partial date of last dose will be handled in the calculation as follows:

- If only the day is missing, then the earlier date of the last day of the month or the date that the participant discontinued treatment will be used.
- If both the month and day are missing, then the earlier date of 31 DEC of the year or the date that the participant discontinued treatment will be used.
- Otherwise, the date that the participant discontinued treatment will be used as the date of the last dose.

When calculating DOR, PFS, and OS, a partial date of death will be handled in the calculation as follows:

- If mmyyyy for the last known alive date = mmyyyy for the death date, then the day after the last known alive date will be used.
- If mmyyyy for the last known alive date < mmyyyy for the death date, then the first day of the death month will be used.
- Otherwise, the partial death date will not be handled.

When calculating time to onset or duration of a TEAE, a partial or missing AE onset/end date will be handled in the calculation as follows:

- If only the day is missing, then the first day of the month or Day 1, whichever is later, will be used as the onset date; the earlier date of the last day of the month or the date that the participant discontinued study or died will be used as the end date.
- If both the month and day are missing, then 01 JAN or Day 1, whichever is later, will be used as the onset date; the earlier date of 31 DEC or the date that the participant discontinued study or died will be used as the end date.
- Otherwise, Day 1 will be used as the onset date, and the missing end date will not be handled.

## 4.2. Variable Definitions

### 4.2.1. Body Mass Index

Body mass index will be calculated as follows:

BMI ($kg/m^2$) = [weight (kg)] / [height (m)]$^2$.

### 4.2.2. Prior and Concomitant Medication

Prior medication is defined as any nonstudy medication started before the first dose of INCB050465.

Concomitant medication is defined as any nonstudy medication that is started accordingly:

- Before the date of first administration of INCB050465 and is ongoing throughout the study or ends on/after the date of first study drug administration.
- On/after the date of first administration of INCB050465 and is ongoing or ends during the course of study.

A prior medication could also be classified as "both prior and concomitant medication" if the end date is on or after first dose of INCB050465. In the listing, it will be indicated whether a medication is prior-only, concomitant-only, or both prior and concomitant.

For the purposes of analysis, all medications will be considered concomitant medications unless the medications can unequivocally be defined as not concomitant.

# 5. STATISTICAL METHODOLOGY

## 5.1. General Methodology

Unless otherwise noted, SAS® software (SAS Institute Inc, Cary, NC; v9 or later) will be used for the generation of all tables, graphs, and statistical analyses. Descriptive summaries for continuous variables will include, but not be limited to, the number of observations, mean, standard deviation, median, minimum, and maximum. Descriptive summaries for categorical variables will include the number and percentage of participants in each category.

Interim analyses are planned for this study as defined in Section 10.

## 5.2. Treatment Groups

This is a Phase 2, multicenter, open-label study. For the purpose of analysis, the 20 mg once weekly dosing period in Group A and the 2.5 mg QD dosing period in Group B are considered maintenance dosing periods. Data will be presented in summary tables by actual received treatment regimen and combined, with an exception for participants who cross over to the selected treatment regimen after the start of the maintenance dosing period. There will not be any statistical comparison between the treatment groups.

For participants who cross over from the initially assigned treatment regimen to the selected treatment regimen, if the crossover happens on/before the start of the maintenance period, then the participant will be summarized, according to the actual received treatment, in the selected treatment regimen; otherwise, the participant will be summarized in:

- A separate treatment regimen (ie, Crossover) for the safety summaries during the maintenance dosing period (eg. summaries of TEAEs and exposure).
- The initially assigned treatment regimen for all other summaries.

## 5.3. Analysis Populations

### 5.3.1. All-Screened Population

The all-screened population includes all participants who signed the informed consent form. The all-screened population will be used for the summary of analysis populations.

### 5.3.2. Full Analysis Set

The FAS includes all participants enrolled in the study who received at least 1 dose of INCB050465.

The FAS will be used for the summary of demographics, baseline characteristics, participant disposition, and analyses of all efficacy data.

### 5.3.3. Safety Population

The safety population includes all participants enrolled in the study who received at least 1 dose of INCB050465.

All safety analyses will be conducted using the safety population.

[redacted]

# 6. BASELINE, EXPOSURE, AND DISPOSITION VARIABLES AND ANALYSES

Appendix A provides a list of planned tables, figures, and listings. Sample data displays are included in a separate document.

## 6.1. Baseline and Demographics, Physical Characteristics, and Disease History

### 6.1.1. Demographics and Baseline Characteristics

The following demographics will be summarized and listed for the FAS: age, sex, race, ethnicity, weight, height, BMI, and geographic region. Eastern Cooperative Oncology Group performance status at baseline will be summarized and listed for the FAS.

### 6.1.2. Disease History

Time since diagnosis, initial grade, initial cytogenetics, initial Ann Arbor staging, initial FLIPI risk category, initial presence of B-symptoms, current grade, current cytogenetics, current Ann Arbor staging, current FLIPI risk category, current presence of B-symptoms, bone marrow involvement at baseline (Yes vs No), bulky disease at baseline (longest diameter ≥ 10 cm vs < 10 cm) at baseline by the IRC, and relapsed/refractory status to the most recent prior therapy

will be summarized and listed for all participants in the FAS. Date of tumor marker tests and test results will be listed.

Time since diagnosis will be calculated as follows:

Time since diagnosis (years) = (Day 1 date – date of diagnosis + 1) / 365.25.

### 6.1.3. Prior Therapy

Number of prior systemic cancer therapy regimens will be summarized for all participants in the FAS. The component drugs of prior systemic therapy regimens will be coded using the WHO Drug Dictionary. Number and percentage of participants with each drug will be summarized by WHO drug class and WHO drug PT. Regimen name, component drugs, start and stop date, route of the medication, best response, reason for discontinuation, and date of relapse/progression will be listed.

Number of participants who received prior radiation will be summarized for the FAS. Anatomical location of the administration, start and stop date, and total dose will be listed.

Number of participants who had prior surgery or surgical procedure for the malignancies under study will be summarized for the FAS. Date and description of the surgery/procedure will be listed.

Number of participants who had prior hematopoietic stem cell transplant will be summarized for the FAS. Date of transplant, type of transplant, source of cells, line of therapy, best response, date of relapse/progression, and regimen and drug used with the transplant will be listed.

### 6.1.4. Medical History

Medical history will be coded to SOC and PT using MedDRA coding dictionary. For participants in the FAS, medical history will be summarized by SOC and PT and listed.

## 6.2. Disposition of Participants

The number and percentage of participants who were treated, who were ongoing with study treatment, who discontinued study treatment with a primary reason for discontinuation, who were still in the study, and who withdrew from the study with a primary reason for withdrawal will be summarized for the FAS.

The number of participants enrolled by country and site will also be provided for the FAS.

## 6.3. Protocol Deviations

Protocol deviations recorded on the eCRF will be summarized and listed for the FAS.

## 6.4. Exposure

For participants in the safety population, exposure to INCB050465 will be summarized descriptively as the following:

- **Duration of treatment (days)**: Date of last dose – date of first dose + 1.

- **Duration of treatment during the initial QD dosing period (days)**: Date of last dose during initial QD dosing period – date of first dose + 1.
- **Duration of treatment during the maintenance dosing period (days)**: Date of last dose – date of first dose during the maintenance dosing period + 1. Crossover participants who switched to the selected treatment regimen after the start of the maintenance dosing period will be summarized in a separate group (ie, Crossover).
- **Average reported daily dose during the initial QD dosing period (mg/day)**: Total reported dose taken during initial QD dosing period (mg) / duration of treatment during the initial QD dosing period (days).
- **Average reported daily dose during the maintenance dosing period (mg/day)**: Total reported dose taken during the maintenance dosing period (mg) / duration of treatment during the maintenance dosing period (days). Crossover participants who switched to the selected treatment regimen after the start of the maintenance dosing period will be summarized in a separate group (ie, Crossover).
- **Dose modifications:** Number of participants who had dose reduction and interruption will be summarized. The number of dose reductions and the number of interruptions for each participant will be summarized.

## 6.5. Study Drug Compliance

For participants in the safety population, overall compliance (%) for INCB050465 will be calculated for all participants as

compliance (%) = 100 × [total dose actually taken] / [total prescribed dose].

The total prescribed dose is defined as the sum of the doses prescribed by the investigator accounting for dose modifications.

The total actual dose taken will be calculated based on information entered on the Drug Accountability CRF. If there are dispensed drugs that have not been returned yet, the actual dose taken starting from the dispense date of the unreturned drugs will be imputed by the dose taken as reported on the dosing CRF.

## 6.6. Prior and Concomitant Medication

Prior medications and concomitant medications will be coded using the WHO Drug Dictionary. Number and percentage of participants in the FAS for each prior and concomitant medication will be summarized by WHO drug class and WHO drug PT.

# 7. EFFICACY

Appendix A provides a list of planned tables, figures, and listings. Sample data displays are included in a separate document.

## 7.1. Efficacy Hypotheses

Not applicable.

## 7.2. Response Assessment

An objective assessment of disease status is required at baseline (screening) using the CT-based response criteria of the Lugano Classification (Cheson et al 2014). Disease status will be subsequently assessed by CT/MRI every 8 weeks through Week 24, then every 12 weeks through Week 96, and then every 24 weeks thereafter until disease progression.

Bone marrow examination is required as a baseline assessment at screening except for reasons provided in Section 7.6.2 of the Protocol. If disease is present in bone marrow at baseline, a bone marrow examination will be required to confirm CR or may be performed as clinically indicated. If the bone marrow does not have lymphoma involvement at baseline, a repeat marrow examination is not required to confirm indication of CR on imaging.

Sites will use the CT-based response criteria of the Lugano Classification (Cheson et al 2014) to assess response to treatment locally. At each postbaseline disease assessment, response will be collected in the eCRF as CR, PR, SD, PD, or NE.

All imaging will be submitted to the IRC. Imaging data and applicable clinical data will be reviewed and response will be assessed using the CT-based response criteria of the Lugano Classification (Cheson et al 2014) by independent reviewers as described in the Independent Review Charter. An overall timepoint response at each postbaseline disease assessment, the best overall response, the date of initial response (if applicable), and the date of progression along with the reason(s) of disease progression (if applicable) for each participant, considering radiographic data and clinical data, will be provided by Clinical Reviewer. These data will be used in the analyses of related efficacy endpoints.

## 7.3. Analysis of the Primary Efficacy Parameter

The primary efficacy analyses will be conducted when all participants in the FAS who have achieved a response (ie, PR or CR) according to the IRC have had approximately 12 months of follow-up from the onset of response.

### 7.3.1. Best Overall Response and Overall Response Rate

For responses determined by the IRC, the best overall response for each participant will be provided by the Clinical Reviewer. A participant is considered an objective responder if they have a best overall response of CR or PR.

The ORR is the proportion of objective responders. Participants who do not have sufficient baseline or on-study response assessment information to be adequately assessed for response status will be included in the denominators in the calculation of ORR.

Best overall response as determined by the IRC will be descriptively summarized by treatment groups and combined. The ORR as determined by the IRC will be estimated with 95% CIs. Confidence intervals will be calculated based on the exact method for binomial distributions.

Because participants who switched to the selected treatment regimen after starting the maintenance dose received a mixture of the non-selected and selected maintenance regimens and could confound the efficacy evaluation of the non-selected treatment regimen, a sensitivity analysis of ORR as determined by IRC will be provided to summarize these crossover participants as a separate treatment regimen. In addition, the number of participants who achieved best overall response as determined by IRC after the time of crossover along with the best overall response data will be presented under this separate treatment regimen.

When applicable, sensitivity analysis of ORR as determined by the IRC may be provided excluding participants that do not have evaluable radiological images at baseline per the IRC.

### 7.3.2. Subgroup Analyses for Objective Response Rate

Subgroups will be formed based on the following participant characteristics and baseline variables for those participants whose data are available:

- Age: $< 65$ years, $\geq 65$ years
- Gender: male, female
- Race: white, others
- Geographic region: Europe, North America, rest of world
- Current FL grade: 1, 2, 3a
- Current Ann Arbor Staging: I-II, III-IV
- Current FLIPI risk category: low (0 - 1), intermediate (2), high ($\geq 3$)
- Number of prior systemic therapy regimens: $< 3$, $\geq 3$
- Bone marrow involvement at baseline: yes, no, unknown
- ECOG performance status: $\leq 1$ vs 2
- Bulky disease at baseline: longest diameter $\geq 10$ cm vs $< 10$ cm at baseline by IRC
- Relapsed/refractory status to the most recent prior therapy: relapsed, refractory, unknown

Subgroups may be further divided or combined based on emerging data. The ORR as determined by IRC and its 95% exact binomial CIs will be provided for participants for each subgroup. A forest plot will be created to summarize the variability in ORR as determined by the IRC for participants across subgroups.

## 7.4. Analysis of the Secondary Efficacy Parameter

### 7.4.1. Complete Response Rate

Complete response rate is the percentage of participants with a best overall response of CR as defined by revised response criteria for lymphomas (Cheson et al 2014). For responses determined by the IRC, the best overall response for each participant will be provided by the Clinical Reviewer. Participants who do not have sufficient baseline or on-study response assessment information to be adequately assessed for response status will be included in the denominators in the calculation of CRR.

The CRR as determined by the IRC will be estimated with 95% CIs. Confidence intervals will be calculated based on the exact method for binomial distributions.

A sensitivity analysis of CRR will be provided to summarize participants who switched to the selected treatment regimen after starting the maintenance dose as a separate treatment regimen.

### 7.4.2. Duration of Response

Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve an objective response (ie, CR or PR), as determined by revised response criteria for lymphomas (Cheson et al 2014). For responses assessed by the IRC, the date of initial response and date of disease progression will be provided by the Clinical Reviewer for participants who have achieved best response of CR or PR. Censoring of DOR will follow the same algorithm as the censoring of PFS (see Section 7.4.3).

The total number of responders per the IRC, the number of participants whose disease progressed per the IRC or who died, and the number of participants censored will be summarized by treatment groups and combined. The Kaplan-Meier estimate of median DOR as determined by the IRC will be presented with its 95% CI, with the CIs calculated using the generalization of Brookmeyer and Crowley's method (1982) with log-log transformation (Klein and Moeschberger 1997).

A sensitivity analysis of DOR will be performed where response assessments after the time of crossover will be excluded from the determination of DOR for participants who switched to the selected treatment regimen after starting the maintenance dose. Crossover participants who have not progressed at the time of crossover will be censored at the last valid radiologic assessment on/before the time of crossover. Participants who failed to achieve a response of CR or PR on/before the time of crossover will not be considered as responders for this analysis.

### 7.4.3. Progression-Free Survival

Progression-free survival is defined as the time from the date of the first dose of the study drug to the first documented disease progression as determined by revised response criteria for lymphomas (Cheson et al 2014), or death due to any cause, whichever occurs first. For responses assessed by IRC, date of disease progression will be provided by the Clinical Reviewer. Censoring for PFS will follow the algorithm outlined in Table 2, which is based on FDA Guidance for Industry: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung

Cancer Drugs and Biologics (2015) and Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018).

**Table 2: Evaluation and Censoring of Progression-Free Survival**

| Situation | Outcome | Date of Progression or Censoring |
|---|---|---|
| No baseline tumor assessments | Censored | Day 1 |
| No valid postbaseline response assessments | Censored | Day 1 |
| Progression documented between scheduled response assessments | Progressed | Date of first overall response of PD |
| No progression | Censored | Date of last valid radiologic assessment (not NE and not missing) |
| Study discontinuation for undocumented progression | Censored | Date of last valid radiologic assessment (not NE and not missing) |
| Study discontinuation for toxicity or other reason | Censored | Date of last valid radiologic assessment (not NE and not missing) |
| New anticancer treatment started | Censored | Date of last valid radiologic assessment (not NE and not missing) on/before starting a new anticancer treatment |
| Death before first progressive response assessment | Progressed | Date of death |
| Death between adequate response assessments | Progressed | Date of death |
| Death or progression after two or more missed assessments | Censored | Date of last valid radiologic assessment (not NE and not missing) before the missed assessments |

NE = not evaluable.

The number of participants whose disease progressed per the IRC or who died, and the number of participants censored will be summarized by treatment groups and combined. The Kaplan-Meier estimate of median PFS as determined by the IRC will be presented with its 95% CIs, with the CIs calculated using the generalization of Brookmeyer and Crowley's method (1982) with log-log transformation (Klein and Moeschberger 1997). Progression-free survival rates at 6, 12, 18, 24, and 36 months will also be provided with 95% CIs calculated using Greenwood's formula to estimate the standard error.

A sensitivity analysis of PFS will be performed where response assessments after the time of crossover will be excluded from the determination of PFS for participants who switched to the selected treatment regimen after starting the maintenance dose. Crossover participants who have not progressed at the time of crossover will be censored at the last valid radiologic assessment on/before the time of crossover.

### 7.4.4. Overall Survival

Overall survival is defined as the time from the date of the first dose of study drug to death due to any cause. For participants who are still alive at the time of the analysis, OS will be censored on the date the participant is last known to be alive.

The number of participants who died and the number of participants censored will be summarized by treatment groups and combined. The Kaplan-Meier estimate of median OS will be presented with its 95% CIs, with the CIs calculated using the generalization of Brookmeyer and Crowley's method (1982) with log-log transformation (Klein and Moeschberger 1997). Survival rates at 6, 12, 18, 24, and 36 months will also be provided with 95% CIs calculated using Greenwood's formula to estimate the standard error.

### 7.4.5. Best Percentage Change in Target Lesion Size

For participants in the FAS with measurable lesions at baseline, target lesion sizes will be measured by the sum of the product of diameters of all target lesions. The best percentage change from baseline, defined as the largest decrease in target lesion sizes during the study, will be summarized by treatment groups and combined. A waterfall plot of the best percentage change (2 treatment groups combined) will be generated using data from the IRC. Note that for participants who only have increases in target lesion sizes from baseline, the smallest increase will be considered as the best change from baseline. For the IRC, two radiologic reviewers will conduct separate reviews for each participant. An adjudication will be performed per the Independent Review Charter when Reviewers 1 and 2 disagree on the CT/MRI best overall response, or when best overall response is consistent, but the date of initial response and/or the date of progression differ between Reviewers 1 and 2. The adjudicator will select the read that he or she believes more accurately reflects the adjudication parameter(s) in question. This is considered the "accepted read," and data from this reviewer will be used for the analysis. When there is no adjudication needed, data from Reviewer 1 will be used for the analysis. An indicator will be provided to identify the read that is considered to be the accepted assessment in data from the IRC.

Best change in target lesion size as reported by the investigator will also be summarized as described above. Target lesions considered "too small to measure" will be assigned a default value of 5 mm × 5 mm for purposes of this analysis. Likewise, target lesions identified as "not present" at postbaseline assessments will be assigned 0 mm × 0 mm for this analysis. In the event that a target lesion is unaccounted for in a particular postbaseline timepoint (ie, the assessment is missing or NE), then the overall sum of target lesions will not be evaluable for that postbaseline timepoint.

[redacted]

[redacted]



# 9. SAFETY AND TOLERABILITY

Appendix A provides a list of planned tables, figures, and listings. Sample data displays are included in a separate document.

## 9.1. General Considerations

Summary tables may be replaced with listings when appropriate. For instance, an AE frequency table may be replaced with a listing if it only contains a few unique preferred terms reported on relatively few participants.

## 9.2. Adverse Events

### 9.2.1. Adverse Event Definitions

A TEAE is any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug and within 30 days of the last administration of study drug regardless of starting new anti-lymphoma therapy. Analysis of AEs (as discussed below) will be limited to TEAEs, but data listings will include all AEs regardless of their timing in relation to study drug administration. For purposes of analysis, all AEs will be considered TEAEs unless the AE can unequivocally be defined as not treatment-emergent.

Adverse events will be tabulated by MedDRA PT and SOC. Severity of AEs will be graded using the NCI CTCAE (v4.03; NCI 2010), Grades 1 through 5. The CTCAE reporting guidelines and grading details are available on the Cancer Therapy Evaluation Program website.

The subset of AEs considered by the investigator to be related to study drug will be considered treatment-related AEs. If the investigator does not specify the relationship of the AE to study drug, the AE will be considered treatment-related. The incidence of AEs and treatment-related AEs will be tabulated. In addition, serious TEAEs will also be tabulated.

### 9.2.2. Adverse Events of Special Interest

The number of participants who experienced TEAEs of special interest listed below will be summarized by maximum severity.

- Colitis
- Diarrhea
- Exfoliative dermatitis
- Febrile neutropenia
- Rash
- Intestinal perforation
- Pneumonitis
- Pneumonia
- PJP infection
- CMV infection
- Herpes simplex
- Varicella zoster virus infection

The time to onset of a TEAE is defined as the interval between the date of first dose of study drug and the date of the first occurrence of a TEAE. Participants who have not experienced a TEAE at the time of analysis will be right-censored at the earlier of 30 days after the last dose date and date of last study visit through the end of safety follow-up. If participants have missing or partial last dose dates of study drug or onset date of a TEAE, the partial or missing dates will be handled using the rules explained in Section 4.1.4.

Summaries of time to onset of new or worsening Grade 3 or higher AEs will be provided using descriptive statistics and the life-table method for rash, colitis, diarrhea, febrile neutropenia, pneumonia, herpes simplex, and varicella zoster virus infection. In addition, summaries of time to onset of new or worsening AEs of any grade will be provided using descriptive statistics and the life-table method for colitis, diarrhea, exfoliative dermatitis, intestinal perforation, pneumonia, pneumonitis, PJP infection, CMV infection, herpes simplex, and varicella zoster virus infection. Kaplan-Meier plots of time to onset of new or worsening Grade 3 or higher AEs will be provided for rash, colitis, and diarrhea. In addition, Kaplan-Meier plots of time to onset of new or worsening AEs of any grade will be provided for colitis and diarrhea.

Descriptive statistics of time to onset of these TEAEs of special interest are based on all participants who have experienced a TEAE at the time of analysis. To summarize these TEAEs of special interest using the life-table method, the effective sample size is defined as the number of participants at the beginning of interval minus half the participants censored in the interval. The conditional proportion is calculated as the number of first events divided by the effective sample size in the interval.

The longest duration of a TEAE of any grade is defined as the longest interval between the date of occurrence of a TEAE and the date of resolution. The longest duration of a Grade 3 or higher TEAE is defined as the longest interval between the date of occurrence of a Grade 3 or higher TEAE and the date of improvement to Grade 2 or lower. If participants have missing or partial onset/end date of a TEAE, the partial or missing dates will be handled using the rules explained in Section 4.1.4. Participants who have missing end date of a TEAE at the time of analysis will be right-censored using the following algorithm:

- If the TEAE is serious, then the participant will be censored at the earlier date of data cutoff, study discontinuation, and death.
- If the TEAE is not serious,
  - If the participant is ongoing with study treatment, then the participant will be censored at the data cutoff date, OR
  - If the participant discontinued treatment, then the participant will be censored at date of safety follow-up visit, or 35 days after the end of treatment visit (or after the last dose if the end of treatment visit was not performed), whichever is later; the censored date will be truncated by the earlier date of data cutoff, study discontinuation, and death if beyond.

Longest duration of new or worsening Grade 3 or higher colitis, diarrhea, rash, and febrile neutropenia will be summarized. In addition, longest duration of new or worsening AEs of any grade will be summarized for colitis, diarrhea, and rash.

The total number of participants whose TEAE of any grade resolved or whose Grade 3 or higher TEAE improved to Grade 2 or lower and the number of participants censored will be summarized. The Kaplan-Meier estimate of median time to resolution/improvement and its 95% CIs will be provided, with the CIs calculated using the generalization of Brookmeyer and Crowley's method (1982) with log-log transformation (Klein and Moeschberger 1997). Resolution/improvement rates at selected timepoints will also be provided with 95% CIs calculated using Greenwood's formula to estimate the standard error.

TEAEs of special interest to be summarized may be adjusted based on emerging data.

### 9.2.3. Adverse Event Summaries

Overall summaries of TEAEs by treatment regimen will be provided during the INCB050465 initial QD dosing period, maintenance dosing period, and overall period (ie. all TEAEs regardless of the timing of occurrence). These summaries will include the following:

- Number (%) of participants reporting any TEAEs
- Number (%) of participants reporting any Grade 3 or higher TEAEs
- Number (%) of participants reporting any serious TEAEs
- Number (%) of participants reporting any TEAEs related to INCB050465
- Number (%) of participants reporting any Grade 3 or higher TEAEs related to INCB050465
- Number (%) of participants reporting any serious TEAEs related to INCB050465

- Number (%) of participants who had TEAE with fatal outcome
- Number (%) of participants with INCB050465 dose reductions because of TEAEs
- Number (%) of participants who temporarily interrupted INCB050465 because of TEAEs
- Number (%) of participants who permanently discontinued INCB050465 because of TEAEs

The following summaries will be produced for TEAEs during the overall period by MedDRA term (if 10 or fewer participants appear in a table, a listing may be appropriate):

- Summary of TEAEs by SOC and PT
- Summary of TEAEs by PT in decreasing order of frequency
- Summary of TEAEs by SOC, PT, and maximum severity
- Summary of TEAEs by PT and maximum severity in decreasing order of frequency
- Summary of Grade 3 or higher TEAEs by SOC and PT
- Summary of Grade 3 or higher TEAEs by PT in decreasing order of frequency
- Summary of serious TEAEs by SOC and PT
- Summary of serious TEAEs by PT in decreasing order of frequency
- Summary of INCB050465 treatment-related TEAEs by SOC and PT
- Summary of INCB050465 treatment-related TEAEs by PT in decreasing order of frequency
- Summary of INCB050465 treatment-related TEAEs by SOC, PT, and maximum severity
- Summary of Grade 3 or higher INCB050465 treatment-related TEAEs by SOC and PT
- Summary of INCB050465 treatment-related serious TEAEs by SOC and PT
- Summary of TEAEs with a fatal outcome by SOC and PT
- Summary of TEAEs leading to INCB050465 dose reduction by SOC and PT
- Summary of TEAEs leading to INCB050465 dose interruption by SOC and PT
- Summary of TEAEs leading to discontinuation of INCB050465 by SOC and PT
- Summary of selected TEAEs of special interest by maximum severity
- Summary of time to onset of selected TEAEs of special interest
- Summary of time to onset of selected TEAEs of special interest: life-table method
- Summary of longest duration of selected TEAEs of special interest

The following supporting summaries will be produced for TEAEs during the INCB050465 initial QD dosing period and the maintenance dosing period by MedDRA term. For the supporting summaries during the maintenance dosing period, participants who cross over to the selected treatment regimen after the start of the maintenance dosing period will be summarized in a separate group (ie, Crossover).

- Summary of TEAEs by PT in decreasing order of frequency
- Summary of TEAEs by PT and maximum severity in decreasing order of frequency
- Summary of Grade 3 or higher TEAEs by PT in decreasing order of frequency
- Summary of serious TEAEs by PT in descending order of frequency
- Summary of TEAEs with a fatal outcome by SOC and PT
- Summary of TEAEs leading to discontinuation of INCB050465 by SOC and PT

## 9.3. Clinical Laboratory Tests

### 9.3.1. Laboratory Value Definitions

Laboratory values and change from baseline values will be summarized descriptively by visit. Baseline will be determined according to Section 4.1.3. If there are multiple values that meet the criteria for baseline, the value from the central laboratory has priority over the value from the local laboratory. Thereafter, additional rules may be provided after consultation with the medical monitor to delineate which value will be defined as baseline.

Laboratory test values will be assessed for severity based on the numerical component of CTCAE v4.03.

### 9.3.2. Laboratory Value Summaries

All test results and associated normal ranges from central laboratories will be reported in SI units. Any laboratory test results and associated normal ranges from local laboratories will be converted to SI units.

When there are multiple laboratory nonmissing values for a participant's particular test at a scheduled visit, central laboratory values have higher priority over local laboratory values. If a tie still exists, the laboratory value with the smallest laboratory sequence number will be used in by-visit summaries.

Numeric laboratory values will be summarized descriptively in SI units, and non-numeric test values will be tabulated when necessary. In addition, line graphs will be provided for ALT, AST, hemoglobin, platelet counts, leukocytes, neutrophils, and lymphocytes.

Shift tables will be presented showing change in CTCAE grade from baseline to worst grade postbaseline. Separate summaries for abnormally high and abnormally low laboratory values will be provided when the laboratory parameter has both high and low grading criteria. The denominator for the percentage calculation will be the number of participants in the baseline category. The number of participants who experienced worsening of laboratory abnormalities will be summarized by maximum postbaseline severity.

### 9.3.3. Potential Hy's Law Events

Participants with elevated ALT or AST > 3 × ULN range and alkaline phosphatase < 2 × ULN range accompanied by total bilirubin > 2 × ULN range at the same visit will be listed by treatment group.

### 9.3.4. Worsening Laboratory Events of Special Interest

Laboratory events of special interest are listed below.

- ALT increased
- AST increased
- Absolute neutrophil count decreased

The time to onset of a worsening laboratory event is defined as the interval between the date of first dose of study drug and the date of the first occurrence of CTC grade worse than baseline for the laboratory event. Participants who have not experienced a worsening laboratory event at the time of analysis will be right-censored at the last postbaseline study visit with nonmissing CTC grade of the laboratory event.

Time to onset of worsening Grade 3 or 4 laboratory events of special interest will be summarized using descriptive statistics and the life-table method as described in Section 9.2.2, and the Kaplan-Meier plot of time to onset of worsening Grade 3 or 4 absolute neutrophil count decreased will be provided. Laboratory events of special interest to be summarized may be adjusted based on emerging data.

## 9.4. Vital Signs

Values at each scheduled visit, change, and percentage change from baseline for vital signs, including weight, systolic blood pressure, diastolic blood pressure, pulse, body temperature, and respiratory rate will be summarized descriptively.

Normal ranges for vital sign values are defined in Table 4. The abnormal values for participants exhibiting vital sign abnormalities will be listed along with their assigned treatment regimen. Alert vital signs are defined as an absolute value outside the defined normal range and percentage change greater than 25%. Note that the definition of alert vital signs does not apply for body temperature and weight. The abnormal values for participants exhibiting alert vital sign abnormalities will be listed.

**Table 4: Normal Ranges for Vital Sign Values**

| Parameter | High Threshold | Low Threshold |
|---|---|---|
| Systolic blood pressure | ≤ 155 mmHg | ≥ 85 mmHg |
| Diastolic blood pressure | ≤ 100 mmHg | ≥ 40 mmHg |
| Pulse | ≤ 100 bpm | ≥ 45 bpm |
| Temperature | ≤ 38°C | ≥ 35°C |
| Respiratory rate | ≤ 24 breaths/min | ≥ 12 breaths/min |

## 9.5. Electrocardiograms

Twelve-lead ECGs including PR, QRS, QT, QTcB, QTcF, and RR intervals will be obtained for each participant during the study. Values at each scheduled visit, change, and percentage change from baseline will be summarized for each ECG parameter. Baseline will be determined as the average of all nonmissing values before the first administration of INCB050465.

Normal ranges for ECG values are defined in Table 5. Electrocardiogram values will also be considered abnormal if the absolute percentage change from baseline is more than 25% (30% for QRS interval). Participants exhibiting ECG abnormalities will be listed with study visit and assigned treatment regimen. Abnormal values for participants with alert ECG values, defined as both the absolute value and the percentage change from baseline being outside normal ranges, will be identified and listed. Outliers of QT, QTcB, and QTcF values, defined as absolute values > 450 milliseconds or change from baseline > 30 milliseconds, will be summarized.

**Table 5: Normal Ranges for Electrocardiogram Values**

| Parameter | High Threshold | Low Threshold |
|---|---|---|
| PR | ≤ 220 ms | ≥ 75 ms |
| QRS | ≤ 120 ms | ≥ 50 ms |
| QT | ≤ 500 ms | ≥ 300 ms |
| QTcB, QTcF | ≤ 450 ms | ≥ 295 ms |
| RR | ≤ 1330 ms | ≥ 600 ms |

QTcB = Bazett's correction; QTcF = Fridericia's correction.

# 10. INTERIM ANALYSES

An interim futility analysis is planned when the first 50 participants (Group A and Group B combined) have been evaluated for response or have permanently discontinued study treatment because of disease progression, withdrawal of consent, or death. The study will be terminated for futility if ≤ 18 of the 50 participants have responded (ie, CR or PR) based on assessments provided by the IRC; otherwise the study will continue. The probability of stopping at interim for futility is 62.16% when the true response rate is 35% or 2.34% when the true response rate is 51%.

An IDMC will be charged with evaluating interim futility results. The IDMC will consist of clinicians and an independent statistician. The IDMC will make recommendations to the sponsor at the planned interim futility analysis. The process by which the IDMC will make recommendations and decisions will be documented in the IDMC charter. Additional operational details of the interim analyses, including tables, figures, and listings provided to the IDMC, will be provided in the IDMC Charter.

There is no efficacy interim analysis planned for the study.

# 11. CHANGES AND MODIFICATIONS TO THE ANALYSIS PLAN

All versions of the SAP are listed in Table 6.

**Table 6: Statistical Analysis Plan Versions**

| SAP Version | Date |
|---|---|
| Original | 01 MAR 2019 |
| Amendment 1 | 26 AUG 2020 |
| Amendment 2 | 28 JAN 2021 |

## 11.1. Changes to Protocol-Defined Analyses

The PP population was removed from the planned analysis. For a single-arm, open-label study, the determination of participants to be excluded from the PP population is post hoc and may not be done objectively; thus, analysis based on this population may not be meaningful.

## 11.2. Changes to the Statistical Analysis Plan

**Amendment 2 (28 JAN 2021)**

**Overall Rationale for the Amendment:** The primary purpose of this amendment is to comply with responses to comments provided by FDA regarding the Statistical Analysis Plan Amendment 1.

- Section 6.4 was updated to include the summary for the number of dose reductions and the number of dose interruptions of each participant.
- Section 7.3.1 was updated to include a sensitivity analysis of ORR that summarizes participants who switched to the selected dose after starting the maintenance dose in a separate treatment regimen and to include an additional analysis on the number of participants who achieved best overall response after the time of crossover along with the best overall response data for this separate treatment regimen.
- Section 7.4.1 was updated to include a sensitivity analysis of CRR by summarizing participants who switched to the selected dose after starting the maintenance dose in a separate treatment regimen.
- Section 7.4.2 and Section 7.4.3 were updated to included sensitivity analyses where response assessments after the time of crossover will be excluded from the determination of DOR and PFS for participants who switched to the selected treatment regimen after starting the maintenance dose.
- Section 9.2.1 was modified to clarify how AEs that occur after new anti-lymphoma therapy will be assessed.
- **Incorporation of minor changes.** Other minor changes have been incorporated throughout the SAP and are noted in the redline version of the amendment.

**Amendment 1 (26 AUG 2020)**

- Section 3 was modified to increase the target enrollment from approximately 100 to approximately 120 participants. This change is to align with recommendations from FDA.
- Section 4.1.4 was updated to include details of rules for handling partial/missing onset or end date of TEAEs in the calculation of time to onset or duration of a TEAE. Rules for partial/missing date of last dose were updated to include details for when both month and day are missing.
- Section 5.2 was modified to provide details regarding how crossover participants will be summarized.
- Section 5.3 was updated to add the all-screened population for the summary of analysis populations.
- Section 6.1.2 was updated to add relapsed/refractory status to the most recent prior therapy to the summary table of disease history because the response to last regimen before entering the study may be a prognostic factor for clinical outcomes.
- Section 6.2 was modified to add summaries of participants who are ongoing with treatment or still in the study.
- Section 6.4 was modified to change the calculations of duration of treatment and average dose during the maintenance dosing period because Group B with 2.5 mg QD was selected as the maintenance dose.
- Section 7.3 was updated to change the timing of the primary analysis to align with recommendations from FDA.
- Section 7.3.2 was modified to add "unknown" as a category for bone marrow involvement at baseline. Relapsed/refractory status to the most recent prior therapy was added to the subgroup analysis because the response to last regimen before entering the study may be a prognostic factor for clinical outcomes.
- Section 7.4.3 was modified to update references of censoring for PFS.
- Section 9.2.2 was updated to include details of analyses on time to onset of selected TEAEs of special interest. Summaries of longest duration of selected TEAEs of special interest were added to have a better understanding of the safety profile in terms of duration of class-effect AEs as well as AEs influenced by treatment regimens. "Grade 2 or higher" was changed to "Grade 3 or higher" for time to onset summary of rash. This change was made to be consistent with other PI3K inhibitors, which highlighted more severe cutaneous reactions graded as Grade 3 or higher in the labeling. "Herpes simplex virus infection" was changed to "herpes simplex" based on the MedDRA coding dictionary as a broader term. Exfoliative dermatitis was added to the list of TEAEs of special interest.

- Section 9.2.3 was updated to include summary of TEAEs by PT and maximum severity in decreasing order of frequency, summary of longest duration of selected TEAEs of special interest, and additional supporting summaries during the INCB050465 initial QD dosing period and the maintenance dosing period, which will provide supportive data of the safety profile of the maintenance dose. Summary of nonserious TEAEs by SOC and PT was removed because it will not be used for the clinical study report but will be provided for result disclosure.
- Section 9.3.2 was modified to include ALT and AST in the line graphs as additional supportive analyses for laboratory events of special interest.
- Section 9.3.3 was added to identify potential Hy's law events to better monitor liver toxicity.
- Section 9.3.4 was updated to align with the analysis plan for adverse events of special interest. Summary of worsening of laboratory events of special interest was removed because this is covered by the summary of worsening of laboratory abnormalities.
- Section 9.5 was updated to change the high threshold of QTcF and QTcB interval from 460 to 450 milliseconds for purpose of analysis. This change is to comply with the categories outlined in FDA Guidance for Industry (E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs) used to characterize outliers in QTc values.

# 12. REFERENCES

Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.

Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068.

Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data, New York, NY: Springer-Verlag; 1997.

National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events Version 4.03. 2010.

# APPENDIX A. PLANNED TABLES, FIGURES, AND LISTINGS

This appendix provides a list of the planned tables, figures, and listings for the Clinical Study Report. Standard tables will follow the conventions in the Standard Safety Tables v1.9. Shells are provided for nonstandard tables in a separate document.

The lists of tables, figures, and listings and the shells are to be used as guidelines. Modifications of the lists that do not otherwise affect the nature of the analysis will not warrant an amendment to the SAP.

## Tables

| Table No. | Title | Population | Standard |
|---|---|---|---|
| **Baseline and Demographic Characteristics** | | | |
| 1.1.1 | Analysis Populations | All-Screened | X |
| 1.1.2 | Summary of Participant Disposition | FAS | X |
| 1.1.3 | Summary of Number of Participants Enrolled by Country and Site | FAS | X |
| 1.1.4 | Summary of Protocol Deviations | FAS | X |
| 1.2.1 | Summary of Demographics and Baseline Characteristics | FAS | X |
| 1.3.1 | Summary of Baseline Disease Characteristics | FAS | X |
| 1.3.2 | Summary of Prior Cancer Therapy | FAS | |
| 1.3.3 | Summary of Prior Systematic Cancer Therapy by WHO Drug Class and Preferred Term | FAS | |
| 1.4.1 | Summary of Prior Medications | FAS | X |
| 1.4.2 | Summary of Concomitant Medications | FAS | X |
| 1.5.1 | Summary of General Medical History | FAS | X |
| **Efficacy** | | | |
| 2.1.1 | Summary of Best Overall Response and Objective/Complete Response Rate as Determined by Independent Review Committee | FAS | |
| 2.1.2 | Summary of Best Overall Response and Objective/Complete Response Rate as Reported by Investigator | FAS | |
| 2.1.3 | Summary of Best Overall Response and Objective Response Rate as Determined by Independent Review Committee by Subgroup | FAS | |
| 2.2.1 | Summary of Duration of Response as Determined by Independent Review Committee | FAS | |
| 2.2.2 | Summary of Duration of Response as Reported by Investigator | FAS | |
| 2.2.3 | Summary of Progression-Free Survival as Determined by Independent Review Committee | FAS | |
| 2.2.4 | Summary of Progression-Free Survival as Reported by Investigator | FAS | |
| 2.2.5 | Summary of Overall Survival | FAS | |
| 2.2.6 | Summary of Best Change in Target Lesion Size as Determined by Independent Review Committee | FAS | |
| 2.2.7 | Summary of Best Change in Target Lesion Size as Reported by Investigator | FAS | |
| [redacted] | | | |

| Table No. | Title | Population | Standard |
|---|---|---|---|
| [redacted] | | | |
| 2.4.1 | Summary of Best Overall Response and Objective/Complete Response Rate as Determined by Independent Review Committee – Crossover as a Separate Treatment Group | FAS | |
| 2.4.2 | Summary of Best Overall Response and Objective/Complete Response Rate as Reported by Investigator – Crossover as a Separate Treatment Group | FAS | |
| 2.4.3 | Summary of Best Overall Response as Determined by Independent Review Committee for Crossover Participants | FAS | |
| 2.4.4 | Summary of Best Overall Response as Reported by Investigator for Crossover Participants | FAS | |
| 2.4.5 | Summary of Duration of Response as Determined by Independent Review Committee – Censoring Crossover Participants | FAS | |
| 2.4.6 | Summary of Duration of Response as Reported by Investigator – Censoring Crossover Participants | FAS | |
| 2.4.7 | Summary of Progression-Free Survival as Determined by Independent Review Committee – Censoring Crossover Participants | FAS | |
| 2.4.8 | Summary of Progression-Free Survival as Reported by Investigator – Censoring Crossover Participants | FAS | |
| **Safety** | | | |
| 3.1.1 | Summary of Exposure and Compliance | Safety | |
| 3.1.2 | Summary of Exposure and Average Daily Dose During Initial QD Dosing Period | Safety | |
| 3.1.3 | Summary of Exposure and Average Daily Dose During Maintenance Dosing Period | Safety | |
| 3.2.1 | Overall Summary of Treatment-Emergent Adverse Events | Safety | X |
| 3.2.2 | Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.3 | Summary of Treatment-Emergent Adverse Events by MedDRA Preferred Term in Decreasing Order of Frequency | Safety | X |
| 3.2.4 | Summary of Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum Severity | Safety | X |
| 3.2.6 | Summary of Grade 3 or Higher Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.7 | Summary of Grade 3 or Higher Treatment-Emergent Adverse Events by Preferred Term in Decreasing Order of Frequency | Safety | X |
| 3.2.8 | Summary of Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.9 | Summary of Serious Treatment-Emergent Adverse Events by Preferred Term in Decreasing Order of Frequency | Safety | X |
| 3.2.10 | Summary of INCB050465 Treatment-Related Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.11 | Summary of INCB050465 Treatment-Related Treatment-Emergent Adverse Events by MedDRA Preferred Term in Decreasing Order of Frequency | Safety | X |

| Table No. | Title | Population | Standard |
|---|---|---|---|
| 3.2.12 | Summary of INCB050465 Treatment-Related Treatment-Emergent Adverse Events by MedDRA System Organ Class, Preferred Term, and Maximum Severity | Safety | X |
| 3.2.14 | Summary of Grade 3 or Higher INCB050465 Treatment-Related Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.15 | Summary of INCB050465 Treatment-Related Serious Treatment-Emergent Adverse Events by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.16 | Summary of Treatment-Emergent Adverse Events With a Fatal Outcome by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.18 | Summary of Treatment-Emergent Adverse Events Leading to INCB050465 Dose Reduction by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.19 | Summary of Treatment-Emergent Adverse Events Leading to INCB050465 Dose Interruption by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.20 | Summary of Treatment-Emergent Adverse Events Leading to Discontinuation of INCB050465 by MedDRA System Organ Class and Preferred Term | Safety | X |
| 3.2.25 | Summary of Treatment-Emergent Adverse Events by MedDRA Preferred Term and Maximum Severity in Decreasing Order of Frequency | Safety | |
| 3.2.26 | Summary of Selected Treatment-Emergent Adverse Events of Special Interest by Maximum Severity | Safety | |
| 3.2.27 | Summary of Time to Onset of Selected Treatment-Emergent Adverse Events of Special Interest | Safety | |
| 3.2.28 | Summary of Time to Onset of Selected Treatment-Emergent Adverse Events of Special Interest: Life-Table Method | Safety | |
| 3.2.29 | Summary of Longest Duration of Selected Treatment-Emergent Adverse Events of Special Interest | Safety | |
| 3.3.1.1 | Summary of Laboratory Values - Hematology | Safety | X |
| 3.3.1.2 | Summary of Laboratory Values - Chemistry | Safety | X |
| 3.3.3.1 | Shift Summary of Hematology Laboratory Values in CTC Grade - To the Worst Abnormal Value | Safety | X |
| 3.3.3.2 | Shift Summary of Chemistry Laboratory Values in CTC Grade - To the Worst Abnormal Value | Safety | X |
| 3.3.3.4 | Treatment-Emergent Worsening of Laboratory Abnormalities - Hematology | Safety | X |
| 3.3.3.5 | Treatment-Emergent Worsening of Laboratory Abnormalities - Chemistry | Safety | X |
| 3.3.6 | Time to Onset of Treatment-Emergent Worsening of Laboratory Events of Special Interest | Safety | |
| 3.3.7 | Time to Onset of Treatment-Emergent Worsening of Laboratory Events of Special Interest: Life-Table Method | Safety | |
| 3.4.1 | Summary of Systolic Blood Pressure | Safety | X |
| 3.4.2 | Summary of Diastolic Blood Pressure | Safety | X |
| 3.4.3 | Summary of Pulse | Safety | X |
| 3.4.4 | Summary of Respiratory Rate | Safety | X |
| 3.4.5 | Summary of Body Temperature | Safety | X |
| 3.4.6 | Summary of Weight | Safety | X |

| Table No. | Title | Population | Standard |
|---|---|---|---|
| 3.5.1 | Summary of PR Interval (ms) From 12-Lead ECG | Safety | X |
| 3.5.2 | Summary of QRS Interval (ms) From 12-Lead ECG | Safety | X |
| 3.5.3 | Summary of QT Interval (ms) From 12-Lead ECG | Safety | X |
| 3.5.4 | Summary of QTcB Interval (ms) From 12-Lead ECG | Safety | X |
| 3.5.5 | Summary of QTcF Interval (ms) From 12-Lead ECG | Safety | X |
| 3.5.6 | Summary of RR Interval (ms) From 12-Lead ECG | Safety | X |
| 3.5.8 | Summary of Outliers of QT, QTcB, and QTcF Interval Values From 12-Lead ECG | Safety | X |
| 3.5.9 | Summary of Clinically Significant ECG Abnormality | Safety | X |

## Figures

| Figure No. | Title |
|---|---|
| 4.1.1 | Forest Plot of Objective Response Rate as Determined by Independent Review Committee |
| 4.2.1 | Kaplan-Meier Estimates of Duration of Response as Determined by Independent Review Committee |
| 4.2.2 | Kaplan-Meier Estimates of Duration of Response as Reported by Investigator |
| 4.2.3 | Kaplan-Meier Estimates of Progression-Free Survival as Determined by Independent Review Committee |
| 4.2.4 | Kaplan-Meier Estimates of Progression-Free Survival as Reported by Investigator |
| 4.2.5 | Kaplan-Meier Estimates of Overall Survival |
| 4.2.6 | Waterfall Plot of Best Percent Change in Sum of Target Lesions as Determined by Independent Review Committee |
| 4.2.7 | Waterfall Plot of Best Percent Change in Sum of Target Lesions as Reported by Investigator |
| 4.3.1 | Kaplan-Meier Estimates of Duration of Response as Determined by Independent Review Committee – Censoring Crossover Participants |
| 4.3.2 | Kaplan-Meier Estimates of Duration of Response as Reported by Investigator – Censoring Crossover Participants |
| 4.3.3 | Kaplan-Meier Estimates of Progression-Free Survival as Determined by Independent Review Committee – Censoring Crossover Participants |
| 4.3.4 | Kaplan-Meier Estimates of Progression-Free Survival as Reported by Investigator – Censoring Crossover Participants |
| 4.5.1 | Kaplan-Meier Estimates of Time to Onset of Selected TEAEs of Special Interest |
| 4.5.2 | Kaplan-Meier Estimates of Longest Duration of Selected TEAEs of Special Interest |
| 4.6.1 | Line Graph of Mean Values Over Time for Selected Laboratory Values (Hemoglobin, Platelet Counts, Leukocytes, Neutrophils, and Lymphocytes) |
| 4.6.2 | Kaplan-Meier Estimates of Time to Onset of Selected Worsening Laboratory Events of Special Interest |

## Listings

| Listing No. | Title |
|---|---|
| 2.1.1 | Participant Enrollment and Disposition Status |
| 2.1.2 | Participant Inclusion and Exclusion Criteria Violations |
| 2.2 | Protocol Deviations |
| 2.3 | Analysis Population |
| 2.4.1 | Demographic and Baseline Characteristics |
| 2.4.2 | Disease History |
| 2.4.3 | Prior Systemic Therapy |
| 2.4.4 | Prior Radiation Treatment |

| Listing No. | Title |
|---|---|
| 2.4.5 | Prior Surgery or Surgical Procedure |
| 2.4.6 | Prior Stem Cell Transplant |
| 2.4.7 | Medical History |
| 2.4.8 | Prior and Concomitant Medication |
| 2.4.9 | Tumor Markers |
| 2.5.1 | Study Drug Compliance |
| 2.5.2 | Study Drug Administration |
| 2.6.1 | Best Overall Response, Duration of Response, and Progression-Free Survival per Independent Review Committee |
| 2.6.2 | Best Overall Response, Duration of Response, and Progression-Free Survival per Investigator |
| 2.6.3 | Overall Response Assessment by Visit per Independent Review Committee |
| 2.6.4 | Independent Review Committee Response Assessment: Target Lesions |
| 2.6.5 | Independent Review Committee Response Assessment: Nontarget Lesions |
| 2.6.6 | Independent Review Committee Response Assessment: New Lesions |
| 2.6.7 | Overall Response Assessment by Visit per Investigator |
| 2.6.8 | Investigator Response Assessment: Target Lesions |
| 2.6.9 | Investigator Response Assessment: Nontarget Lesions |
| 2.6.10 | Investigator Response Assessment: New Lesions |
| 2.6.11 | Deaths and Overall Survival |
| 2.6.12 | Bone Marrow Examination |
| [redacted] | [redacted] |
| 2.6.14 | Best Overall Response, Duration of Response, and Progression-Free Survival per Independent Review Committee – Censoring Crossover Participants |
| 2.6.15 | Best Overall Response, Duration of Response, and Progression-Free Survival per Investigator – Censoring Crossover Participants |
| 2.7.1 | Adverse Events |
| 2.7.2 | Serious Adverse Events |
| 2.7.3 | Grade 3 and Higher Adverse Events |
| 2.7.4 | Fatal Adverse Events |
| 2.7.5 | Treatment-Related Adverse Events |
| 2.7.6 | Adverse Events Leading to Interruption, Reduction or Discontinuation of INCB050465 |
| 2.8.1 | Clinical Laboratory Values - Hematology |
| 2.8.2 | Clinical Laboratory Values - Chemistry |
| 2.8.3 | Abnormal Clinical Laboratory Values - Hematology |
| 2.8.4 | Abnormal Clinical Laboratory Values - Chemistry |
| 2.8.5 | Potential Hy's Law Events |
| 2.9.1 | Vital Signs |
| 2.9.2 | Abnormal Vital Sign Values |
| 2.9.3 | Alert Vital Sign Values |
| 2.10.1 | 12-Lead ECG Values |
| 2.10.2 | Abnormal 12-Lead ECG Values |
| 2.10.3 | Alert 12-Lead ECG Values |